PubMed Health⌕ Search

Biomedical subjects

M Hradsky

Publications and source records attributed to M Hradsky.

At least 19 recordsLinked to original sources
PubMed1989

Campylobacter pylori and non-ulcer dyspepsia. 2. A prospective study in a Swedish population.

In a consecutive prospective series of 186 Swedish persons with the diagnosis of non-ulcer dyspepsia 71.5% were found to have gastritis and/or bulbar duodenitis in endoscopic biopsies. Gastroduodenitis was associated with campylobacter pylori (CP) in 83.5% of the cases. The double therapeutic approach using an antibiotic and a preparation containing bismuth in an uncontrolled therapeutic pilot trial resulted in improvement of the histological picture, disappearance of CP and amelioration of symptoms. It is concluded that CP-infection plays a central role in the pathogenesis of gastroduodenitis associated NUD.

Adult↗
PubMed1989

Campylobacter pylori and gastroduodenal ulcer disease. A prospective study in a Swedish population.

In a consecutive prospective series of 208 Swedish primary peptic ulcer patients, 146 gastric, 55 duodenal and 7 in both sites, gastroduodenitis was found in 97.6% of the cases. The mucosal inflammation was associated with CP in 87% and 91% of the gastric and duodenal ulcer cases respectively. No significant correlation was found between CP colonisation and the type or severity of mucosal inflammation. Gastric metaplasia was present in only 8% of 48 bulbar ulcer cases. Ulcer healing and eradication of CP was achieved in 52% of patients treated with bismuth subnitrate in combination with erythromycin or according to the triple approach.

Adult↗
PubMed1988

The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms.

In a Swedish double-blind multicentre study, omeprazole (30 mg o.m.) was compared with the H2-receptor antagonist cimetidine (400 mg b.d.) in 152 patients. Clinical assessments and laboratory investigations were carried out at 2 and 4 weeks, and again at 6 weeks in unhealed patients. Endoscopy was performed at 2 weeks, and again at 4 and 6 weeks in unhealed patients. The patients in the two groups were well-matched prior to treatment. Omeprazole was superior to cimetidine in ulcer-healing rate after 2, 4 and 6 weeks. After 2 weeks of treatment, 66% of the omeprazole- and 45% of the cimetidine-treated patients were healed (P = 0.02), after 4 weeks 97 and 84% (P = 0.01), and after 6 weeks 100 and 92% (P = 0.02), respectively. There was a more pronounced improvement in the patients' symptoms in the omeprazole group after 2 weeks (P = 0.05). Both drugs were well-tolerated, but there was a high prevalence of patients with adverse events in the cimetidine group (51%, compared to 30% of the omeprazole group; P = 0.02). A total of 125 patients were followed for 6 months after healing. The patients were investigated by endoscopy after 6 months, or whenever symptoms occurred. There was no significant difference in the rate of relapse within 6 months between the two treatment groups: 54% relapsed in the omeprazole group and 52% in the cimetidine group. In conclusion, 30 mg of omeprazole, given once daily, is superior to 400 mg of cimetidine twice daily in duodenal ulcer healing; but ulcer relapse in the two groups appears to be equivalent.

Adolescent↗
PubMed1988

The intragastric milieu during gastric ulcer treatment with pirenzepine 50 mg b.i.d. or cimetidine 400 mg b.i.d.

In a double-blind randomised four-center trial 43 patients with gastric ulcer (20 men, 23 women; mean age 52.2 years) were treated with either pirenzepine (P) 50 mg b.i.d. (n = 24) or cimetidine (C) 400 mg b.i.d. (n = 19) during six weeks. In ten patients gastric juice was examined before and at the end of the treatment for concentration and type of the microbial flora, and for nitrite concentration. After six weeks 83% of the patients in both groups were either symptom-free or clearly improved. In 15/24 patients on P (62.6%) and in 13/18 on C (72.2%) the ulcer(s) were healed at the time of control endoscopy. In the ten patients investigated, intragastric concentrations of fungi, bacteria, and nitrite were not significantly changed by the treatment. In gastric ulcer, treatment with pirenzepine 50 mg b.i.d. or cimetidine 400 mg b.i.d. during six weeks does not result in significant microbial overgrowth or generation of nitrite.

Adult↗
PubMed1985

Ulcer healing and relapse prevention by ranitidine in peptic ulcer disease.

Ranitidine, 300 mg daily, was given to 92 patients with duodenal ulcer (DU), 38 with prepyloric ulcer (PPU), and 21 with gastric corporeal ulcer (GCU). The healing rates at 4 weeks differed for the different types of ulcers (P less than 0.01), being 91% for DU, 68% for PPU, and 81% for GCU. After established ulcer healing, maintenance treatment with either ranitidine, 100 mg twice daily or 150 mg at night, or placebo was given for 1 year or until ulcer relapse in a total of 108 patients--71 with DU, 24 with PPU, and 13 with GCU. There were no significant differences in relapse rates between the two groups treated with active drug or between the three ulcer groups. However, the overall relapse rate in the active drug groups was 16%, against 72% in the placebo group (P less than 0.001).

Antacids↗
PubMed1985

Pirenzepine versus cimetidine in duodenal ulcer treatment. A clinical and microbiological study.

The therapeutic efficacy of pirenzepine (PIR) and cimetidine (CIM) in duodenal ulcer and their effects on the intragastric milieu have been studied in a double-blind multicentre trial. Seventy-nine patients with endoscopically proven duodenal ulcer were randomly allocated to 4 weeks' treatment with either 50 mg PIR twice daily or 400 mg CIM twice daily. In addition to clinical and endoscopic evaluation and registration of side effects and laboratory test results, endoscopically obtained gastric juice was cultured and its nitrite concentration was measured before and at the end of the treatment. Seventy-five patients completed the study. The treatment groups were comparable with regard to age, sex, smoking habits, and consumption of coffee and alcohol. After 4 weeks, 27 of 37 patients (73%) in the PIR group were completely healed, compared with 29 of 38 (76%) in the CIM group (NS). The number of patients with side effects was similar in both groups, but side effects of antimuscarinic type were more frequently reported by patients in the PIR group. Intragastric microbial concentrations increased significantly during treatment in both groups but remained well within normal limits. No single nitrite concentration before or after treatment exceeded the normal range. In conclusion, the two drugs were about equally effective in the short-term treatment of duodenal ulcer disease. In the doses given they did not adversely affect the intragastric milieu.

Aged↗
PubMed1982

Effect of pirenzepine in the treatment of non-ulcer dyspepsia. A double-blind study.

The effectiveness of pirenzepine at 50 mg daily in the treatment of non-ulcer dyspepsia was assessed in a double-blind 4-weeks clinical trial against placebo. 59 patients entered the trial of whom 11 defaulted or were withdrawn. 48 patients completed the trial. Clinical and laboratory assessment were performed on admission to the study and after 4 weeks treatment. The results of this double-blind comparative trial show that pirenzepine in a daily dose of 50 mg is very effective and significantly more effective than placebo in the treatment of non-ulcer dyspepsia.

Adult↗
PubMed1981

Endoscopic evaluation of gastric tolerance to fenclofenac.

Gastrointestinal irritation is a common consequence of treatment with many non-steroidal anti-inflammatory agents. An open tolerance study with endoscopic control employing fenclofenac in doses of 900 or 1200 mg daily in ten patients with osteoarthrosis, was carried out over an eight week period. The principal aim of the study was to evaluate the effect of fenclofenac on the gastroduodenal mucosa in a selected group of patients with osteoarthrosis and with a history of gastric intolerance to other non-steroidal anti-inflammatory agents. All patients tolerated fenclofenac well and showed clinical improvement.

Adult↗
PubMed1979

Healing of duodenal ulcer during treatment with an anticholinergic and an antacid.

Twenty-nine patients with endoscopically proven duodenal ulcers were treated with either placebo or benzilonium bromide (Ulcoban prolongatum) for 4 weeks. Antacid consumption was low in both groups. Healing after 4 weeks was verified endoscopically and was about equal for both treatments. Frequency of pain and other "dyspeptic" symptoms appeared to be less in patients treated with benzilonium. Lack of symptoms was not always associated with healing of the ulcers.

Antacids↗
PubMed1978

The effect of metoclopramide (Primperan) on the pyloric sphincter during gastroscopic examination. A double blind investigation versus placebo.

The effect of metoclopramide and placebo on relaxation of a spasmodic pylorus during gastroscopy have been compared using a double blind technique. Metoclopramide showed a better result and the difference between its effect and the effect of placebo is statistically significant (p less than 0.01). Metoclopramide is a useful agent during gastroscopic examination in cases of spasmodic pylorus. It facilitates the passage of the gestroscope through the spasmodic pyloric sphincter. The reported relaxation and dilatation of the pyloric sphincter clarifies the amelioration of symptoms in different gastrointestinal troubles.

Adult↗
PubMed1978

Endoscopic evaluation of the effect of azapropazone on the gastric mucosa.

The gastro-intestinal tolerance of azapropazone, a new non-steroidal anti-inflammatory agent, was studied endoscopically in 14 volunteers with no past history of gastro-intestinal disease. This study shows that gastrointestinal tolerance to azapropazone given in a daily dose of 1200 mg for a period of 31 days is good. Istolated erosions with mild hyperemia were found in 2 subjects only. No subjective symptoms were noted during the period of the study.

Apazone↗